Top Back to top

A comparison between ATG and PT-CY graft-versus-host-disease prophylaxis in patients with lymphoma undergoing reduced intensity conditioning regimen HSCT from 1 antigen MMUD

Lymphoma Working Party (LWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Allogeneic - Unrelated
Short title:
ATG vs PT-Cy in 1 MMUD
Primary objective:
To retrospectively analyze outcomes after first allogenic hematopoietic stem cell transplantation (HSCT) from MMUD 9/10 with a reduced intensity conditioning (RIC) regimen comparing outcomes of PT-CY versus ATG as GVHD prophylaxis in patients with lymphoproliferative disorders
Key inclusion criteria:
Inclusion criteria:
-Patients who received a 9/10 HSCT
-First HSCT (previous autologous transplantation accepted)
-High-resolution HLA allele typing at loci A, B, C, DRB1 and DQ available
-Stem Cell source (bone marrow or peripheral blood stem cells)
-Year of HSCT from 2010 to 2018
-All type of B and T cell lymphomas (NHL and HL, aggressive and indolent)
-All disease status at HSCT
-RIC regimen
-In vivo T cell depletion (TCD) with ATG (other in vivo TCD excluded) or PT-CY

Exclusion criteria:
-Cord Blood as stem cell source
-Other type of unrelated HSCT (matched unrelated, more than 1 mismatch)
Principal investigator:
Annalisa Paviglianiti
EBMT Study coordinator:
Hervé Finel
Study coordinator email: